FAQ Directory: HEDIS

Filter Results
  • Save

    Save your favorite pages and receive notifications whenever they’re updated.

    You will be prompted to log in to your NCQA account.

  • Email

    Share this page with a friend or colleague by Email.

    We do not share your information with third parties.

  • Print

    Print this page.

10.15.2017 ECDS How are ECDS measures different from the eMeasures in Meaningful Use?

HEDIS ECDS and eClinical Quality Measures (eCQM) developed for Meaningful Use are specified using the same data standards. eCQMs are specifically designed to use data extracted from an EHR, and HEDIS ECDS measures use multiple data sources to complete the picture of member experience across the care continuum.

HEDIS 2018

9.15.2017 Transitions of Care Are Special Needs Plans (SNPs) and Medicare-Medicaid Plans (MMPs) required to report the Transitions of Care (TRC) measure?

No. In the 2018 CMS Reporting Requirements Memo, the TRC measure is not listed in Table 3, “HEDIS 2018 Measures for Reporting by SNPs and MMP PBPs.”

HEDIS 2018

8.15.2017 Breast Cancer Screening, Colorectal Cancer Screening, Controlling High Blood Pressure, and Osteoporosis Management in Women Who Had a Fracture A required exclusion was added to the Medicare product line for members 65 years of age and older living long-term in institutional settings for the Breast Cancer Screening, Colorectal Cancer Screening, Controlling High Blood Pressure and Osteoporosis Management in Women Who Had a Fracture measures. In addition to using the Medicare monthly membership file, may organizations use other data sources when identifying members living long-term in an institution?

No. Organizations may not use other data sources (e.g., supplemental or medical record data) when excluding members living long-term in an institution. The LTI flag in the Medicare Part C monthly membership file is the only source that may be used to identify this exclusion. NCQA was informed by CMS that all Medicare plans receive this file monthly and have access to this flag. NCQA plans to clarify this in the HEDIS 2018, Volume 2 Technical Update Memo, scheduled for release on October 2, 2017.

HEDIS 2018

8.15.2017 Use of Opioids From Multiple Providers The Use of Opioids From Multiple Providers (UOP) measure instructs organizations to use the National Provider Identifier (NPI) when identifying prescribers and pharmacies. How should organizations report pharmacy claims for opioids when the prescribing provider and/or pharmacy NPI is missing?

If the prescriber and/or pharmacy NPI is missing, count each dispensing event with a missing NPI as a different prescriber and/or different pharmacy when reporting the measure. NCQA plans to clarify this in the HEDIS 2018, Volume 2 Technical Update Memo, scheduled for release on October 2, 2017.

HEDIS 2018

4.14.2017 Comprehensive Diabetes Care Please clarify the instruction to not include BP readings taken on the same day as a diagnostic test or procedure that requires a change in diet or medication. Must the change in diet or medication be required by the procedure? Is the BP eligible if a patient forgets to take their regular medication the day of a procedure? Is the BP eligible if the member receives a vaccine, a nebulizer treatment with albuterol or lidocaine injected prior to an unplanned removal of a small mole?

The intent is to identify diagnostic or therapeutic procedures that require a medication regimen, a change in diet or a change in medication. For example, colonoscopy requires a change in diet (NPO on the day of procedure) and a medication change (a medication is taken to prep the colon). Dialysis, infusions and chemotherapy are all therapeutic procedures that require a medication regimen. A nebulizer treatment with albuterol is considered a therapeutic procedure that requires a medication regimen (the albuterol). Injection of lidocaine prior to mole removal is considered a diagnostic procedure (if the mole is being tested) or a therapeutic procedure (if removal of the mole is the treatment) that requires a change in medication (lidocaine administered for pain control during the procedure). A patient forgetting to take regular medications on the day of the procedure is not considered a required change in medication, and therefore the BP reading is eligible.

 A BP taken on the same day that the patient receives a vaccination is eligible for use. A vaccination is considered preventive medicine and is not considered a therapeutic or diagnostic procedure.

HEDIS 2017

4.14.2017 Controlling High Blood Pressure Please clarify the instruction to not include BP readings taken on the same day as a diagnostic test or procedure that requires a change in diet or medication. Must the change in diet or medication be required by the procedure? Is the BP eligible if a patient forgets to take their regular medication the day of a procedure? Is the BP eligible if the member receives a vaccine, a nebulizer treatment with albuterol or lidocaine injected prior to an unplanned removal of a small mole?

The intent is to identify diagnostic or therapeutic procedures that require a medication regimen, a change in diet or a change in medication. For example, colonoscopy requires a change in diet (NPO on the day of procedure) and a medication change (a medication is taken to prep the colon). Dialysis, infusions and chemotherapy are all therapeutic procedures that require a medication regimen. A nebulizer treatment with albuterol is considered a therapeutic procedure that requires a medication regimen (the albuterol). Injection of lidocaine prior to mole removal is considered a diagnostic procedure (if the mole is being tested) or a therapeutic procedure (if removal of the mole is the treatment) that requires a change in medication (lidocaine administered for pain control during the procedure). A patient forgetting to take regular medications on the day of the procedure is not considered a required change in medication, and therefore the BP reading is eligible.

 A BP taken on the same day that the patient receives a vaccination is eligible for use. A vaccination is considered preventive medicine and is not considered a therapeutic or diagnostic procedure.

HEDIS 2017

2.15.2017 Adolescent Well-Care Visits Does documentation of “Tanner stage” meet criteria for the physical exam or physical developmental history component for the Adolescent Well-Care Visits (AWC) measure?

Yes. Documentation of Tanner stage meets criteria for the physical exam and physical developmental components, but should not be double-counted toward both (if used as evidence of physical exam, it may not be used as evidence of physical developmental, and vice versa). Documentation of Tanner stage does not meet criteria for the Well-Child Visits in the First 15 Months of Life (W15) or Well-Child Visits in the Third, Fourth, Fifth and Sixth Years of Life (W34) measures as sexual maturity rating is not recommended until 7 years of age.

HEDIS 2017

2.15.2017 Standardized Healthcare-Associated Infection Ratio In Table HAI-1/2/3, the four columns labeled “Percentage of Total Discharges From ...”. are collected in IDSS using 4 digits after the decimal. Because the columns are percentages, how should the data for these columns be displayed? For example, using HAI-1: Central line associated blood stream infection (CLABSI), if there are 100 contracted hospitals, of which 10 belong to “high” category of Standard Infection Ratio, what should the reported value be?
A) 0.1000
B) 10.0000

Option A. Organizations should report results as a decimal; therefore, option A is correct when reporting in IDSS. IDSS will include a validation that checks for values to be reported between 0 and 1 and must be rounded to 4 decimal places.

HEDIS 2017

2.15.2017 Standardized Healthcare-Associated Infection Ratio When reporting the columns “Percentage of Total Discharges From Hospitals With Unavailable SIR,” “Number of Contracted Hospitals With Reportable SIR” and “Total Inpatient Discharges” in Table HAI-1/2/3, if a hospital is not listed in Table HSIR, is it included in the count?

Hospitals for which plans have discharges from but are not identifiable in Table HSIR should not be included in the hospitals reported in the category "Number of Contracted Hospitals With Reportable SIR." However, discharges from these hospitals should be included in “Total Inpatient Discharges” and in “Percentage of Total Discharges From Hospitals With Unavailable SIR.” Use Table HSIR posted on the NCQA Web site to make the determination; organizations do not need to refer to the Hospital Compare web site.

HEDIS 2017

1.15.2017 Reporting the Aspirin Use and Discussion measure for HEDIS 2017 Will NCQA collect or report results for the Aspirin Use and Discussion measure for HEDIS 2017?

No. NCQA has decided to retire the Aspirin Use and Discussion (ASP) measure due to misalignment with updated recommendations from the United States Preventive Services Task Force (USPSTF). The updated USPSTF aspirin recommendations include a calculation of 10-year cardiovascular risk and an estimate of 10-year life expectancy. This information would be required to identify the denominator of the ASP measure and because it cannot be captured in the Consumer Assessment of Healthcare Providers & Systems (CAHPS) Health Plan Survey or claims data, we are unable to adapt the measure to be consistent with the USPSTF findings.

 

The aspirin questions remain in the HEDIS 2017 CAHPS questionnaire but member responses to the questions will not be submitted to NCQA by the certified survey vendor. The questions will be removed from the HEDIS 2018 CAHPS questionnaire.

HEDIS 2017

1.15.2017 Statin Therapy for Patients With Cardiovascular Disease There appear to be additional NDC codes for high- and moderate-intensity statins included in the NDC list for SPD-A that are not in SPC-B. May these additional codes be mapped to the HEDIS 2017 NDC list for table SPC-B?

Yes. Organizations may map NDC codes so that the same set of codes for high-intensity and moderate-intensity statins are used for both the SPC-B and SPD-A measures. An NDC code that is not on the HEDIS list may be used if its generic name, strength/dose and route match an NDC code on the HEDIS list. Organizations should document the method used to map codes: Mapping is subject to review during a HEDIS Compliance Audit. Requirements for mapping are described in General Guideline 50 in HEDIS 2017 Volume 2.

HEDIS 2017

1.15.2017 Reporting RRU Measures for HEDIS 2017 Should health plans report the RRU measures for HEDIS 2017?

No. NCQA suspended collection of the RRU measures for HEDIS 2017 and health plans should not report RRU measures for HEDIS 2017. In 2017 NCQA will decide whether to permanently retire these measures. NCQA will hold a public comment process to aid in the decision. 

HEDIS 2017